Polymorph screening of an active material.
暂无分享,去创建一个
R. Ambrus | Z. Aigner | P. Szabó-Révész | R Ambrus | P Szabó-Révész | P Láng | V Kiss | G Farkas | Z Aigner | E Várkonyi | P. Lang | E. Várkonyi | V. Kiss | G. Farkas | Z. Aigner | Péter Lang | Gabriella Farkas
[1] D. Bugay. Characterization of the solid-state: spectroscopic techniques. , 2001, Advanced drug delivery reviews.
[2] A. Blackburn,et al. One-solvent polymorph screen of carbamazepine. , 2008, International journal of pharmaceutics.
[3] Jukka Rantanen,et al. Solid form screening--a review. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[4] Stephen R Byrn,et al. Solid-state analysis of the active pharmaceutical ingredient in drug products. , 2003, Drug discovery today.
[5] R. Tan,et al. Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy. , 2011, International journal of pharmaceutics.
[6] P. Bennema,et al. The solubility behaviour and thermodynamic relations of the three forms of Venlafaxine free base. , 2009, International journal of pharmaceutics.
[7] Ivan Marziano,et al. Towards a PAT-Based Strategy for Crystallization Development , 2005 .
[8] W. Mccrone,et al. Pharmaceutical applications of polymorphism. , 1969, Journal of pharmaceutical sciences.
[9] G A Stephenson,et al. Characterization of the solid state: quantitative issues. , 2001, Advanced drug delivery reviews.
[10] Changquan Calvin Sun. Solid-state properties and crystallization behavior of PHA-739521 polymorphs. , 2006, International journal of pharmaceutics.
[11] C. Kontoyannis,et al. Analysis and stability of polymorphs in tablets: The case of Risperidone. , 2007, Talanta.
[12] Thomas Rades,et al. An overview of recent studies on the analysis of pharmaceutical polymorphs. , 2011, Journal of pharmaceutical and biomedical analysis.
[13] Keith R Horspool,et al. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. , 2010, Journal of pharmaceutical sciences.
[14] A. Bansal,et al. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. , 2006, Journal of pharmaceutical sciences.
[15] Thomas Rades,et al. Perspectives in the use of spectroscopy to characterise pharmaceutical solids. , 2008, International journal of pharmaceutics.
[16] Markus Schulz,et al. Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] H. Brittain. Polymorphism in Pharmaceutical Solids , 1999 .
[18] B. Stensland,et al. Thermodynamic stability and crystal structures for polymorphs and solvates of formoterol fumarate. , 2006, Journal of pharmaceutical sciences.
[19] Joel Bernstein,et al. Polymorphism in Molecular Crystals , 2002 .